The union government on Sunday suspended the export of Remdesivir injections and Remdesivir Active Pharmaceutical Ingredients (API) till the coronavirus situation improves in the country.
India has been witnessing unprecedented spike in coronavirus cases and on Sunday, the country reported over 150,000 new infections. As on April 11, there are 1.1 million active cases and they are steadily increasing.
"The current situation has led to a sudden spike in demand for Remdesivir injection used in treatment of Covid patients. There is a potential of further increase in this demand in the coming days," the government said in a release.
Seven Indian companies are producing Remdesivir injections under voluntary licensing agreement with US-based Gilead Sciences. They have an installed capacity of about 3.88 million units per month.
In addition, the government has taken the further steps to ensure easy access of hospital and patients to Remdesivir
All domestic manufactures of Remdesivir have been advised to display on their website, details of their stock lists or distributors to facilitate access to the drug.
Drugs inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb hoarding and black marketing.
The State Health Secretaries will review this with the Drug Inspectors of the respective states and Union Territories.
The government said that the department of pharmaceuticals has been in contact with the domestic manufacturers to ramp up the production of Remdesivir.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU